Lundbeck announces European Medicines Agency acceptance of marketing authorization application for eptinezumab for the prevention of migraine
Valby, Denmark, 22 December 2020 – Today, H. Lundbeck A/S (Lundbeck) announces acceptance of the filing for Vyepti™ (eptinezumab-jjmr) by the European Medicines Agency (EMA) for marketing authorization application (MAA) review. The filing seeks approval to introduce Vyepti to European citizens who live with migraine and are eligible for preventative therapy. Vyepti is the most recent strategic brand added to Lundbeck’s portfolio of treatments. As a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), Vyepti prevents CGRP from binding to its receptor, and